No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RXRX240719C7000
- 1.42
- +0.62+77.50%
15min DelayClose Jul 12 16:00 ET
1.60High0.90Low
0.95Open0.80Pre Close278 Volume444 Open Interest7.00Strike Price37.19KTurnover128.60%IV0.72%PremiumJul 19, 2024Expiry Date1.36Intrinsic Value100Multiplier5DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.8817Delta0.1464Gamma5.77Leverage Ratio-0.0238Theta0.0009Rho5.08Eff Leverage0.0021Vega
Intraday
- 5D
- Daily
News
Is Recursion Pharmaceuticals Stock a Buy?
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
Trending Industry Today: Recursion Pharmaceuticals Leads Gains In NVIDIA Holdings Stocks
July 12th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending up in regular trading hours with 4 constituents up and Recursion Pharmaceuticals leading Gains.$Recursion Pharmaceuticals(RXRX.
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $12
KeyBanc analyst Scott Schoenhaus maintains $Recursion Pharmaceuticals(RXRX.US)$ with a buy rating, and adjusts the target price from $16 to $12.According to TipRanks data, the analyst has a success
Express News | Keybanc Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $12
Comments
Last week, Nvidia $NVIDIA(NVDA.US$ briefly eclipsed Microsoft $Microsoft(MSFT.US$ as the world’s most valuable company. The AI chip maker is now worth $3.3 trillion… or roughly the combined value of every residential property in the state of Florida. Shares trade for 50 times forward earnings.
That caused expected hand-wringing on Wall Street.
“We’re not necessarily at peak bubble levels,” said Jonathan Stubbs of Berenberg, a wealth management fi...
That caused expected hand-wringing on Wall Street.
“We’re not necessarily at peak bubble levels,” said Jonathan Stubbs of Berenberg, a wealth management fi...
34
2
$Recursion Pharmaceuticals(RXRX.US$
prospectus of secondary offering resolves two key areas in 4-6 quarters with funds coveing potentially dozensof clinical trials as well as acquisitions.
In May, Recursion also stated that they have future partnerships as well as current partners whose trials include non-dilutive funding as these clical trials progress.
Increased my stake by 15%![]()
prospectus of secondary offering resolves two key areas in 4-6 quarters with funds coveing potentially dozensof clinical trials as well as acquisitions.
In May, Recursion also stated that they have future partnerships as well as current partners whose trials include non-dilutive funding as these clical trials progress.
Increased my stake by 15%
7
$Recursion Pharmaceuticals (RXRX.US)$ raising fund kill the willingness & excitement of small investors like myself.
$Palantir(PLTR.US$ : ”...It’s one big, giant black box except for the consumer product goods company, so I’m going to have to say there’s other people better to ask.”
$GameStop(GME.US$ : “GameStop raised enough money off the backs of the apes, the memes, the kitties — whatever — that they can reinvent the company. If they reinvent the company, then you’re absolutely right. They have such a big war chest that they can just close all ...
$GameStop(GME.US$ : “GameStop raised enough money off the backs of the apes, the memes, the kitties — whatever — that they can reinvent the company. If they reinvent the company, then you’re absolutely right. They have such a big war chest that they can just close all ...
3
Read more